A detailed history of Orbimed Advisors LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 954,500 shares of SRPT stock, worth $99.8 Million. This represents 2.81% of its overall portfolio holdings.

Number of Shares
954,500
Previous 646,000 47.76%
Holding current value
$99.8 Million
Previous $102 Million 16.8%
% of portfolio
2.81%
Previous 2.46%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$124.33 - $156.75 $38.4 Million - $48.4 Million
308,500 Added 47.76%
954,500 $119 Million
Q2 2024

Aug 14, 2024

SELL
$113.33 - $163.85 $5.84 Million - $8.44 Million
-51,500 Reduced 7.38%
646,000 $102 Million
Q4 2023

Feb 14, 2024

BUY
$67.31 - $124.76 $11.3 Million - $21 Million
168,300 Added 31.8%
697,500 $67.3 Million
Q3 2023

Nov 14, 2023

SELL
$102.5 - $123.59 $12.8 Million - $15.4 Million
-124,800 Reduced 19.08%
529,200 $64.1 Million
Q2 2023

Aug 14, 2023

SELL
$106.4 - $157.19 $22.5 Million - $33.2 Million
-211,100 Reduced 24.4%
654,000 $74.9 Million
Q1 2023

May 15, 2023

SELL
$117.53 - $155.99 $12.6 Million - $16.7 Million
-107,200 Reduced 11.03%
865,100 $119 Million
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $5.43 Million - $7.11 Million
53,800 Added 5.86%
972,300 $126 Million
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $68 Million - $107 Million
898,500 Added 4492.5%
918,500 $102 Million
Q2 2022

Aug 15, 2022

SELL
$62.69 - $88.44 $1.2 Million - $1.69 Million
-19,100 Reduced 48.85%
20,000 $1.5 Million
Q1 2022

May 16, 2022

SELL
$63.15 - $90.42 $1.24 Million - $1.77 Million
-19,600 Reduced 33.39%
39,100 $3.05 Million
Q4 2021

Feb 14, 2022

SELL
$77.28 - $99.42 $463,680 - $596,520
-6,000 Reduced 9.27%
58,700 $5.29 Million
Q2 2021

Aug 16, 2021

SELL
$69.38 - $86.75 $9.41 Million - $11.8 Million
-135,578 Reduced 67.69%
64,700 $5.03 Million
Q1 2021

May 17, 2021

SELL
$72.25 - $168.95 $24.5 Million - $57.2 Million
-338,771 Reduced 62.85%
200,278 $14.9 Million
Q3 2020

Nov 16, 2020

SELL
$127.12 - $172.34 $2.62 Million - $3.55 Million
-20,600 Reduced 3.68%
539,049 $75.7 Million
Q2 2020

Aug 14, 2020

SELL
$93.0 - $171.7 $31.9 Million - $58.9 Million
-342,800 Reduced 37.99%
559,649 $89.7 Million
Q1 2020

May 15, 2020

BUY
$82.38 - $131.64 $11.2 Million - $18 Million
136,400 Added 17.81%
902,449 $88.3 Million
Q4 2019

Feb 14, 2020

SELL
$76.53 - $135.58 $5.46 Million - $9.67 Million
-71,300 Reduced 8.51%
766,049 $98.9 Million
Q3 2019

Nov 14, 2019

BUY
$72.81 - $156.91 $651,576 - $1.4 Million
8,949 Added 1.08%
837,349 $63.1 Million
Q1 2019

May 15, 2019

BUY
$106.67 - $151.68 $5.06 Million - $7.19 Million
47,400 Added 6.07%
828,400 $98.7 Million
Q4 2018

Feb 14, 2019

SELL
$97.32 - $148.76 $7.14 Million - $10.9 Million
-73,400 Reduced 8.59%
781,000 $85.2 Million
Q3 2018

Nov 14, 2018

BUY
$115.31 - $161.51 $46.3 Million - $64.9 Million
401,800 Added 88.78%
854,400 $138 Million
Q2 2018

Aug 14, 2018

BUY
$71.74 - $153.69 $9.4 Million - $20.1 Million
131,000 Added 40.73%
452,600 $59.8 Million
Q1 2018

May 15, 2018

BUY
$54.02 - $82.27 $12 Million - $18.3 Million
222,200 Added 223.54%
321,600 $23.8 Million
Q4 2017

Feb 14, 2018

BUY
$47.64 - $56.75 $4.74 Million - $5.64 Million
99,400
99,400 $5.53 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.